Stockscreener 앱 받기
1.52
5.00%
-0.08
시간 외 거래:
1.52
Neumora Therapeutics Inc 주식(NMRA)의 최신 뉴스
Neumora (NASDAQ: NMRA) to sell 146K shares via Merrill Lynch - Stock Titan
1,849,445 Shares in Neumora Therapeutics, Inc. $NMRA Purchased by Johnson & Johnson - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Upgraded at Wall Street Zen - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Announces Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Neumora Therapeutics Appoints Joshua Pinto as CEO and Releases Q2 2026 Financial Results - Kalkine Media
Neumora Therapeutics Releases Q2 2026 Financial Results - news.alphastreet.com
8-K: Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updatemoomoo - moomoo.com
Neumora Therapeutics Cuts Q2 Net Loss to $41.3M on Lower R&D Spend - Minichart
Neumora Appoints New CEO as Q2 Net Loss Narrows to $43.1M - Minichart
Neumora Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Neumora Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Neumora Therapeutics Q2 Results: Net loss narrows to $43.1 million - scanx.trade
Neumora Therapeutics 2Q 2026: Net loss $(43.1M), EPS $(0.23) — 10-Q Summary - TradingView
Neumora Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
NMRA: Pipeline advanced, net loss narrowed, and cash runway extends into Q3 2027 - TradingView
Neumora Therapeutics Reports Second Quarter 2026 Results and Advances Pipeline Amid Leadership Changes - Quiver Quantitative
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - marketscreener.com
Neumora Names Joshua Pinto CEO as 2026 Clinical Milestones Near - Stock Titan
Neumora Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
NMRA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutic - The National Law Review
Neumora Therapeutics (NMRA) Gains 2.48% as Biotech Stock Holds Above $1.57 SupportCatalyst Driven Stocks - dars.gov.et
Perceptive Advisors LLC Takes $9.95 Million Position in Neumora Therapeutics, Inc. $NMRA - MarketBeat
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY) and Fortrea Holdings Inc. (FTRE) - The Globe and Mail
Neumora Therapeutics, Inc. Revenue Breakdown – NASDAQ:NMRA - TradingView
Neumora Therapeutics Inc. (NMRA) Q1 2026 Earnings: Narrower-Than-Expected Loss on Cost Discipline, Shares SlipMargin Compression Risk - dars.gov.et
Neumora Therapeutics (NMRA) Expected to Release Earnings on Wednesday - MarketBeat
H.C. Wainwright reiterates Neumora stock rating on positive toxicology data By Investing.com - Investing.com Nigeria
Neumora reports favorable toxicology results for obesity drug By Investing.com - Investing.com Nigeria
Neumora Therapeutics | 8-K: Current report - Moomoo
Neumora Therapeutics Shares Rise on Positive Obesity Drug Results - Moomoo
NMRA|Neumora Therapeutics Inc|Price:1.456|Chg%:-0.034 - TradingKey
New toxicology data support advancement of Neumora Therapeutics’ NMRA-215 - BioWorld News
Neumora Therapeutics Plans Q4 IND Filing for Obesity Drug After Repeat Toxicology Study - marketscreener.com
Neumora reports favorable toxicology results for obesity drug - Investing.com
Neumora Therapeutics Reports Favorable Repeat Toxicology Results for NMRA-215 and Plans IND Submission in Q4 2026 - Quiver Quantitative
Neumora's Repeat NMRA-215 Rat Study Found No Unexpected Adverse Findings - Stock Titan
Neumora Therapeutics Inc (NMRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neumora Therapeutics Inc (NMRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NMRA|Neumora Therapeutics Inc|Price:1.490|Chg%:-0.070 - TradingKey
Neumora Therapeutics Inc (NMRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neumora Therapeutics Inc (NMRA) Cash Flow - TradingKey
TradingKey - TradingKey
Neumora Therapeutics (NASDAQ:NMRA) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Siren L.L.C. Buys 2,209,039 Shares of Neumora Therapeutics, Inc. $NMRA - MarketBeat
Faruqi & Faruqi Reminds Neumora Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7. 2025NMRA - TMX Newsfile
Neumora Therapeutics (NMRA) AGM 2026 Summary - Quartr
Neumora Therapeutics Target of Unusually Large Options Trading (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics (NMRA) Slides to $1.6 as Biotech Sector Headwinds PersistReversal Setup Alerts - dars.gov.et
Neumora Therapeutics (NASDAQ:NMRA) Price Target Cut to $5.00 by Analysts at Royal Bank Of Canada - MarketBeat
Neumora Therapeutics Is Maintained at Outperform by RBC Capital - Moomoo
RBC Cuts Price Target on Neumora Therapeutics to $5 From $7, Keeps Outperform, Speculative Risk - marketscreener.com
RBC Capital maintains Outperform on Neumora, cuts target to $5 - scanx.trade
Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation - Yahoo Finance
Neumora Therapeutics (NMRA) Edges Higher Amid Modest Gains, Holds Near Key SupportPut Flow Alert - dars.gov.et
A Quick Look at Today's Ratings for Neumora Therapeutics(NMRA.US), With a Forecast Between $5 to $7 - Moomoo
Neumora Therapeutics (NMRA) Stock Slides 3.76% as Biotech Sentiment Remains FragileMcClellan Summation - dars.gov.et
Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy - Yahoo Finance
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2000 Index - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2500 Growth Benchmark - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2000 Growth Benchmark - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 3000E Growth Benchmark - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell Microcap Index - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2500 Index - marketscreener.com
Neumora Therapeutics Inc (NMRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of - The National Law Review
NMRA Slides As Neumora Kills Navacaprant After Phase 3 Blowup - StocksToTrade
1.80%
1.77%
자본화:
|
볼륨(24시간):